Grutters JPC, Sculpher M, Briggs AH, Severens JL, Candel MJ, Stahl JE, De Ruysscher D, Boer A, Ramaekers BLT, Joore MA. Acknowledging patient heterogeneity in economic evaluation. Pharmacoeconomics. 2013;31:111–23. https://doi.org/10.1007/s40273-012-0015-4.

Article  PubMed  Google Scholar 

Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006.

Book  Google Scholar 

Ramaekers BLT, Joore MA, Grutters JPC. How should we deal with patient heterogeneity in economic evaluation: a systematic review of national pharmacoeconomic guidelines. Value Health. 2013;16:855–62. https://doi.org/10.1016/J.JVAL.2013.02.013.

Article  PubMed  Google Scholar 

Espinoza MA, Sculpher MJ, Manca A, Basu A. Analysing heterogeneity to support decision making. In: Encyclopedia of Health Economics. Elsevier; 2004. p. 71–6.

Varadhan R, Seeger JD, et al. Estimation and reporting of heterogeneity of treatment effects. In: Velentgas P, Dreyer NA, Nourjah P, et al., editors. Developing a protocol for observational comparative effectiveness research: a user’s guide. Rockville: Agency for Healthcare Research and Quality; 2013.

Google Scholar 

Dahan M, Scemama C, Porcher R, Biau DJ. Reporting of heterogeneity of treatment effect in cohort studies: a review of the literature. BMC Med Res Methodol. 2018;18:1–11. https://doi.org/10.1186/S12874-017-0466-6/TABLES/5.

Article  Google Scholar 

Espinoza MA, Manca A, Claxton K, Sculpher MJ. The value of heterogeneity for cost-effectiveness subgroup analysis: conceptual framework and application. Med Decis Mak. 2014;34:951–64. https://doi.org/10.1177/0272989X14538705.

Article  Google Scholar 

Palmer S, Raftery J. Opportunity cost. BMJ. 1999;318:1551. https://doi.org/10.1136/bmj.318.7197.1551.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Basu A, Grieve R, Pritchard D, Stevens W. One size does not always fit all in value assessment. Am J Manag Care. 2019;25(11):540–2. https://doi.org/10.1001/jama.2016.11237.

Article  PubMed  Google Scholar 

Jain R, Grabner M, Onukwugha E. Sensitivity analysis in cost-effectiveness studies: from guidelines to practice. Pharmacoeconomics. 2011;29:297–314. https://doi.org/10.2165/11584630-000000000-00000.

Article  PubMed  Google Scholar 

Ramaekers B, Grutters JJM. Acknowledging patient heterogeneity in health technology assessment. OA Epidemiol. 2014;2(1):3.

Google Scholar 

Lavelle TA, Kent DM, Lundquist CM, Thorat T, Cohen JT, Wong JB, Olchanski N, Neumann PJ. Patient variability seldom assessed in cost-effectiveness studies. Med Decis Making. 2018;38:487–94. https://doi.org/10.1177/0272989X17746989.

Article  PubMed  PubMed Central  Google Scholar 

Basu A, Grieve R, Pritchard D, Stevens W. One size does not always fit all in value assessment. Am J Manag Care. 2019;25:540–2.

PubMed  Google Scholar 

Watts RD, Li IW. Use of checklists in reviews of health economic evaluations, 2010 to 2018. Value Health. 2019;22:377–82. https://doi.org/10.1016/j.jval.2018.10.006.

Article  PubMed  Google Scholar 

Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. Br Med J. 1996;313:275–83.

Article  CAS  Google Scholar 

Drummond M, Schulpher M, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 4th ed. Oxford: Oxford University Press; 2015.

Google Scholar 

Evers S, Goossens M, de Vet H, van Tulder M, Ament A. Criteria list for assessment of methodological quality of economic evaluations: consensus on health economic criteria. Int J Technol Assess Health Care. 2005;21:240–5. https://doi.org/10.1017/s0266462305050324.

Article  PubMed  Google Scholar 

Philips Z, Bojke L, Sculpher M, Claxton K, Golder S. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics. 2006;24:355–71.

Article  PubMed  Google Scholar 

Vemer P, Corro Ramos I, van Voorn GAK, Al MJ, Feenstra TL. AdViSHE: a validation-assessment tool of health-economic models for decision makers and model users. Pharmacoeconomics. 2016;34:349–61. https://doi.org/10.1007/s40273-015-0327-2.

Article  CAS  PubMed  Google Scholar 

Chiou CF, Hay JW, Wallace JF, Bloom BS, Neumann PJ, Sullivan SD, Yu HT, Keeler EB, Henning JM, Ofman JJ. Development and validation of a grading system for the quality of cost-effectiveness studies. Med Care. 2003;41:32–44. https://doi.org/10.1097/00005650-200301000-00007.

Article  PubMed  Google Scholar 

Sculpher M, Gafni A. Recognizing diversity in public preferences: the use of preference sub-groups in cost-effectiveness analysis. Health Econ. 2001;10:317–24. https://doi.org/10.1002/hec.592.

Article  CAS  PubMed  Google Scholar 

Zaric GS. The impact of ignoring population heterogeneity when Markov models are used in cost-effectiveness analysis. Med Decis Making. 2003;23:379–96. https://doi.org/10.1177/0272989X03256883.

Article  PubMed  Google Scholar 

Spiegelhalter DJ, Best NG. Bayesian approaches to multiple sources of evidence and uncertainty in complex cost-effectiveness modelling. Stat Med. 2003;22:3687–709. https://doi.org/10.1002/SIM.1586.

Article  PubMed  Google Scholar 

Brennan A, Chick SE, Davies R. A taxonomy of model structures for economic evaluation of health technologies. Health Econ. 2006;15:1295–310. https://doi.org/10.1002/hec.1148.

Article  PubMed  Google Scholar 

Heeg BMS, Damen J, Buskens E, Caleo S, De Charro F, Van Hout BA. Modelling approaches: the case of schizophrenia. Pharmacoeconomics. 2008;26(8):633–48. https://doi.org/10.2165/00019053-200826080-00002.

Article  PubMed  Google Scholar 

Hoch JS, Briggs AH, Willan AR. Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. Health Econ. 2002;11:415–30. https://doi.org/10.1002/hec.678.

Article  PubMed  Google Scholar 

Willan AR, Briggs AH, Hoch JS. Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data. Health Econ. 2004;13:461–75. https://doi.org/10.1002/hec.843.

Article  PubMed  Google Scholar 

Nixon RM, Thompson SG. Methods for incorporating covariate adjustment, subgroup analysis and between-centre differences into cost-effectiveness evaluations. Health Econ. 2005;14:1217–29. https://doi.org/10.1002/hec.1008.

Article  PubMed  Google Scholar 

Drummond M. Methods for the economic evaluation of health care programmes. 3rd ed. New York: Oxford University Press; 2005.

Hoch JS, Dewa CS. Lessons from trial-based cost-effectiveness analyses of mental health interventions: why uncertainty about the outcome, estimate and willingness to pay matters. Pharmacoeconomics. 2007;25:807–16. https://doi.org/10.2165/00019053-200725100-00001.

Article  PubMed  Google Scholar 

Marshall DA, Hux M. Design and analysis issues for economic analysis alongside clinical trials. Med Care 2009;47(7 Suppl 1):S14–20. https://doi.org/10.1097/MLR.0b013e3181a31971.

Glick HA, Doshi JA, Sonnad SS, Polsky D. Economic evaluation in clinical trials. Oxford: Oxford University Press; 2007.

Google Scholar 

Coyle D, Buxton MJ, O’Brien BJ. Stratified cost-effectiveness analysis: a framework for establishing efficient limited use criteria. Health Econ. 2003;12:421–7. https://doi.org/10.1002/hec.788.

Article  PubMed  Google Scholar 

Basu A, Meltzer D. Value of information on preference heterogeneity and individualized care. Med Decis Mak. 2007;27:112–27. https://doi.org/10.1177/0272989X06297393.

Article  Google Scholar 

Sculpher M. Subgroups and heterogeneity in cost-effectiveness analysis. Pharmacoeconomics. 2008;26:799–806.

Article  PubMed  Google Scholar 

Padula WV, Kreif N, Vanness DJ, Adamson B, Rueda JD, Felizzi F, Jonsson P, IJzerman MJ, Butte A, Crown W. Machine learning methods in health economics and outcomes research—the PALISADE checklist: a good practices report of an ISPOR task force. Value Health. 2022;25:1063–80. https://doi.org/10.1016/J.JVAL.2022.03.022.

Article  PubMed  Google Scholar 

Oehrlein EM, Schoch S, Burcu M, McBeth JF, Bright J, Pashos CL, Willke R, Love TR, Mattingly TJ, Perfetto EM. Developing patient-centered real-world evidence: emerging methods recommendations from a consensus process. Value Health. 2023;26:28–38. https://doi.org/10.1016/j.jval.2022.04.1738.

Article  PubMed  Google Scholar 

Veenstra DL, Mandelblatt J, Neumann P, Basu A, Peterson JF, Ramsey SD. Health economics tools and precision medicine: opportunities and challenges. Forum Health Econ Policy. 2020. https://doi.org/10.1515/fhep-2019-0013.

Article  PubMed  Google Scholar 

Gavan SP, Thompson AJ, Payne K. The economic case for precision medicine. Expert Rev Precis Med Drug Dev. 2018;3:1–9. https://doi.org/10.1080/23808993.2018.1421858.

Article  PubMed  PubMed Central  Google Scholar 

Ginsburg GS, Phillips KA. Precision medicine: from science to value. Health Aff. 2018;37:694–701. https://doi.org/10.1377/hlthaff.2017.1624.

Article  Google Scholar 

Pataky RE, Bryan S, Sadatsafavi M, Peacock S, Regier DA. Tools for the economic evaluation of precision medicine: a scoping review of frameworks for valuing heterogeneity-informed decisions. Pharmacoeconomics. 2022;40:931–41. https://doi.org/10.1007/S40273-022-01176-0.

Article  PubMed  Google Scholar 

Briggs AH, Weinstein MC, Fenwick EAL, Karnon J, Sculpher MJ, Paltiel AD. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. Med Decis Making. 2012;32:722–32. https://doi.org/10.1177/0272989X12458348.

Article  PubMed  Google Scholar 

Alshreef A, Latimer N, Tappenden P, Wong R, Hughes D, Fotheringham J, Dixon S. Statistical methods for adjusting estimates of treatment effectiveness for patie